Anticoagulant Tube
Anticoagulant Tube - Related Videos
07:08
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
0 Views •
Cited by 6 •
2017
We present an in vitro model which allows the study and analysis of coagulation in whole, non-anticoagulated blood. Anticoagulation in the system depends on the natural anticoagulation effect of healthy endothelial cells and endothelial cell activation will result in clotting.
01:18
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
0 Views •
2024
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban. Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
0 Views •
2012
Demonstration of a rapid quantitative assay of the inhibition of blood coagulation by the low-molecular-weight-heparin, enoxaparin. The contribution of enoxaparin is assessed by removing its influence through digestion with heparinase. A fuller description of the assay is detailed in our published paper.1 The assay still requires clinical confirmation.
10:56
Tube Thoracostomy
0 Views •
2023
Source: Rachel Liu, BAO, MBBCh, Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA Tube thoracostomy (chest tube placement) is a procedure during which a hollow tube is inserted into the thoracic cavity for drainage of fluid or air. Emergency chest tube insertion is performed for definitive treatment of tension pneumothorax, traumatic hemothorax, large-volume pleural effusions, and empyemas. Irrespective of the cause of air and fluid accumulation in the pleural space, the...
01:30
Anticoagulant Drugs: Low-Molecular-Weight Heparins
0 Views •
2024
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
FAQs
EDTA prevents coagulation by binding calcium, an essential component of the clotting process. This mechanism helps maintain blood in a whole-blood state for laboratory analysis. In cancer research, that preservation can support hematology and immune-cell profiling when cellular measurements require a sample that has not formed a clot.
Heparin inhibits thrombin and related clotting reactions, whereas citrate temporarily chelates calcium under controlled conditions. These distinct mechanisms can influence which sample type is appropriate for a particular investigation. Understanding the difference helps researchers match the anticoagulant with analyses requiring preserved plasma, whole blood, or controlled coagulation conditions.
The additive can determine whether the collected material remains suitable for cellular, molecular, or plasma-based analysis. An inappropriate choice may compromise sample integrity and reduce the reliability of results. For cancer studies, matching the tube to the intended measurement supports investigations of circulating tumor DNA, other circulating components, immune cells, and plasma biomarkers.
The intended specimen and analytical goal are central considerations. Researchers should determine whether the study requires whole blood, plasma, hematology measurements, immune-cell profiling, or molecular analysis of circulating material. They then select among EDTA, heparin, and citrate according to the anticoagulant mechanism and the preservation needs of that investigation.
A typical workflow begins by identifying the planned analysis, selecting a compatible anticoagulant tube, and collecting the blood so the additive can preserve the required sample form. The resulting whole blood or plasma can then support hematology, immune-cell profiling, plasma biomarker studies, or analysis of circulating tumor DNA and related components.
These samples can provide material for several research readouts, including blood-cell measurements, immune-cell characterization, plasma biomarker assessment, and molecular examination of circulating tumor DNA or other circulating components. Their value depends on preserving sample integrity and using an anticoagulant whose mechanism fits the cellular or molecular investigation.